ClinicalTrials.gg
RecruitingNCT07614022Updated Oct 29, 2026

A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)

A Phase 1 interventional study of LP-118 in Philadelphia Positive Acute Lymphoblastic Leukemia, sponsored by Wake Forest University Health Sciences. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Wake Forest University Health Sciences · Phase 1, Interventional, and Treatment

How we know

Updated Oct 29, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Wake Forest University Health Sciences — 3 open to participants now, 3 under way, none of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Wake Forest University Health Sciences.

Planned enrollment
10th of 16
26 · median 40
Started
2026
the only one that year
Phase 1
6 of 19
1 open now
Registered
18th of 19
by date

Among the 19 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Wake Forest University Health Sciences, this one is the 10th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2026, is one of 6 in phase 1, and was the 18th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

3 of the 19 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Wake Forest University Health Sciences, or all of them as a file.
02

Study summary

The purpose of this research study is to see if a drug called LP-118 is safe and effective for treating adults with Philadelphia chromosome-positive (Ph+) B cell acute lymphoblastic leukemia (ALL), when given with ponatinib, dexamethasone, methotrexate and blinatumomab (the standard treatment for this type of cancer).

Read the detailed description

Philadelphia-Chromosome/BCR::ABL1-Positive (Ph+) acute lymphoblastic leukemia (ALL) is a type of blood cancer that happens when a specific genetic change occurs in the DNA of certain blood cells, leading to uncontrolled growth of cells. Ph+ ALL is a more aggressive form of leukemia compared to other types but with specific medications called tyrosine kinase inhibitors, treatment outcomes have significantly improved. Unfortunately, some patients still do experience relapsed disease, when their leukemia comes back after treatment, which is challenging to treat. Therefore, research is ongoing to determine ways to improve therapy and outcomes for patients with Ph+ ALL.

The purpose of this study is to learn more about LP-118 and its side effects and decide on acceptable doses when combined with Food and Drug Administration (FDA) approved therapy for adult patients with Ph+ ALL. All participants will receive standard of care treatment for newly diagnosed Ph+ ALL consisting of the FDA approved drugs ponatinib, dexamethasone, intrathecal (injection into the spinal canal, also called "spinal tap") and systemic methotrexate and blinatumomab. This study will investigate different dose levels of LP-118 when given with his treatment combination to determine the most effective doses that can be safely given to patients with Ph+ ALL. This means that enrolled patients will receive progressive increasing or decreasing doses of LP-118 until the highest effective and safe dose is determined, while closely monitoring patients for any side effects or reactions. The highest dose is the dose that is the most effective dose that can be safely given to patients. This study will also preliminarily investigate if the addition of LP-118 improves treatment responses and outcomes for patients. If this trial is successful, the effectiveness of LP-118 added to this treatment regimen to treat Ph+ ALL will be studied in the next phase of clinical trials.

03

Conditions studied

  • Philadelphia Positive Acute Lymphoblastic Leukemia

Keywords

  • Leukemia
  • Philadelphia-Chromosome positive
  • cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand and willingness to sign an IRB-approved .
  • Age ≥ 18 years at the time of consent.
  • Performance Status (PS) ≤ 2.
  • Histological or cytological confirmation of newly diagnosed CD19-positive Philadelphia-chromosome/BCR::ABL1-positive ALL.
  • : ≥60 mL/min, determined by the Cockroft-Gault formula, or measured by a 24-hour urine collection.
  • ≤ 1.5 × (ULN) - Unless liver abnormalities considered due to Gilbert's syndrome or of non-hepatic origin i.e., leukemic involvement. For patients with Gilbert's syndrome, bilirubin ≤1.5 x of their baseline bilirubin level will be required.
  • (AST) - Unless liver abnormalities considered due to Gilbert's syndrome or of non-hepatic origin i.e., leukemic involvement. For patients with Gilbert's syndrome, bilirubin ≤1.5 x of their baseline bilirubin level will be required.
  • Alanine aminotransferase (ALT) - Unless liver abnormalities considered due to Gilbert's syndrome or of non-hepatic origin i.e., leukemic involvement. For patients with Gilbert's syndrome, bilirubin ≤1.5 x of their baseline bilirubin level will be required.
  • Individuals of (ICBP) must have a negative serum pregnancy test. NOTE: Individuals who may become pregnant are considered to have childbearing potential unless they are surgically infertile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are (at least 12 consecutive months with no menses without an alternative medical cause).
  • ICBP must be willing to use two forms of , one of which must be a barrier method and the other must be a highly effective contraceptive method from the time of informed consent until 6 months after study treatment discontinuation. Male participants with female partners of will need to agree to use contraception methods described above during study treatment and for at least 6 months after completion of all study treatment.
  • Male participants must agree to refrain from sperm donation during study treatment and for at least 6 months after completion of all study treatment.
  • Ability to ingest oral medications without a malabsorption condition, known dysphagia, short-gut syndrome, gastroparesis, or other conditions that may limit the ingestion or gastrointestinal absorption, distribution, metabolism and excretion of drugs administered orally, per the enrolling investigator.

Exclusion criteria

Exclusion Criteria:

  • Any prior treatment for ALL except for a single dose of intrathecal (IT) chemotherapy, , hydroxyurea, a single dose of vincristine, cytarabine, leukapheresis, and/or a BCR::ABL1-targeted tyrosine kinase inhibitor. Permitted prior treatment is limited to a duration of no longer than 14 days. Permitted prior treatment must be stopped at least 24 hours prior to starting study therapy.
  • Women who are pregnant, nursing, or who plan to become pregnant while in the study and for at least 6 months after the last administration of all study treatment. NOTE: breast milk cannot be stored for future use while the mother is being treated on study. Pregnant participants are excluded from this study because ponatinib, blinatumomab, and methotrexate have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ponatinib, blinatumomab, and methotrexate breastfeeding should be discontinued if the patient is treated with ponatinib, blinatumomab, and methotrexate.
  • Active second except for localized prostate cancer, basal cell or squamous cell carcinoma of the skin and carcinoma in situ of the skin or cervix.
  • Unstable or severe uncontrolled medical condition in the opinion of the enrolling investigator (e.g., unstable cardiac function or unstable pulmonary condition; uncontrolled infection).
  • Participants with known history of virus, virus, or (HIV) are eligible if no evidence of active viral replication by blood testing (i.e. negative viral loads). HIV positive participants must be on active anti-retroviral therapy and willing to continue therapy during study treatment.
  • Uncontrolled cardiac disease as determined by the enrolling investigator.
  • Major surgery, as determined by the enrolling investigator, within 2 weeks before enrollment.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Combination of LP-118, ponatinib, dexamethasone, blinatumomab and methotrexate

    LP-118 will be given as tablets of 10mg or 100mg during the induction II course only in combination with ponatinib, dexamethasone, methotrexate and blinatumomab. . Ponatinib, dexamethasone and methotrexate dosing will remain fixed, whereas LP-118 dosing will be dependent on the dose level to which a participant is assigned.

    Drug: LP-118

Interventions

  • DrugNexatoclaxStudies of NexatoclaxNexatoclax pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    s LP-118 dosing will be dependent on the dose level to which a participant is assigned: * 50mg PO * 100mg PO * 200mg PO * 300mg PO

06

What researchers measure

Primary outcomes

  1. Estimation of the Maximum Tolerated Dose (MTD) for LP-118 (Dose Escalation)

    Binary variable indicating if a Dose Limiting Toxicity (DLT) occurred.

    Time frame: The DLT monitoring period is from Day 1 of Course 2 until the end of Course 2 (approximately 21 days).

  2. Identification of the Recommended Phase 2 Dose (RP2D) LP-118 (Dose Expansion)

    Binary variable indicating if a Dose Limiting Toxicity (DLT) occurred.

    Time frame: The DLT monitoring period is from Day 1 of Course 2 until the end of Course 2 (approximately 21 days).

Secondary outcomes

  1. Overall Survival (OS).

    The time from treatment administration to death from any cause, or until last contact if the patient has not died

    Time frame: At most 10 years.

  2. Relapsed-Free Survival (RFS).

    Time from Complete Remission (CR) or Complete Remission with Incomplete Hematologic Recovery (CRi) to disease relapse or death (whichever occurs first) or otherwise censored at the date of the last disease assessment.

    Time frame: At most 10 years.

  3. Event-Free Survival (EFS).

    Time from start of therapy until failure to achieve CR/CRi, relapse, or death from any cause or otherwise censored at the date of the last disease assessment.

    Time frame: At most 10 years.

  4. Overall Complete Molecular Response (CMR) rate.

    Binary variable indicating if a CMR at any time while on study.

    Time frame: At most 10 years.

  5. Measurable Residual Disease (MRD) rate.

    Binary variable indicating if MRD was achieved.

    Time frame: Approximately 3 years.

  6. Isolated Central Nervous System (CNS) relapse rate.

    Binary variable indicating if isolated CNS relapse occurred.

    Time frame: At most 10 years.

  7. Complete Response (CR) rate.

    Complete clinical remission defined as the disappearance of leukemia as indicated by \<5% marrow blasts and the absence of peripheral blasts or extramedullary disease, with recovery of hematopoiesis defined by Absolute Neutrophil Count (ANC) ≥1000/μL and platelets ≥100,000/μL.

    Time frame: Approximately 3 years.

  8. Complete clinical remission with incomplete count recovery (CRi)

    Complete clinical remission with incomplete count recovery (CRi) defined as complete clinical remission except with ANC\< 1000/μL and/or platelets \<100,000/μL

    Time frame: Approximately 3 years.

  9. Overall Response (OR) rate.

    A binary variable indicating if a CR or CRi was achieved.

    Time frame: Approximately 3 years.

  10. Occurrence of toxicities per Common Terminology Criteria V5.0

    Binary variables indicating the occurrence of toxicities per Common Terminology Criteria V5.0.

    Time frame: Approximately 3 years.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Mar 2030, 39 months later.

Of 158 non-industry phase 1 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 92. This study's planned 39 months is below that.

Counting every sponsor, half of 208 studies reached it within 55 months; a quarter within 34 and three quarters within 90.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
May 29, 2026
StartEst.
Dec 2026was Oct 2026
Primary completionEst.
Mar 2030
CompletionEst.
Mar 2030
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 29, 2026
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Atrium Health Levine Cancer · Charlotte, United Statesno status→Recruiting
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center · Winston-Salem, United Statesno status→Recruiting
Oct 29, 2026
Start date
Oct 2026→Dec 2026
Oct 27, 2026
Show all 2 updates
  1. Oct 29, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Atrium Health Levine Cancer · Charlotte, United Statesno status→Recruiting
    • Atrium Health Wake Forest Baptist Comprehensive Cancer Center · Winston-Salem, United Statesno status→Recruiting
  2. Oct 27, 2026
    Start date Oct 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07614022
Collaborators
Newave Pharmaceutical Inc, Atrium Health Wake Forest Baptist, National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Dec 2026 (estimated)
Primary completion
Mar 2030 (estimated)
Completion
Mar 2030 (estimated)
Last update
Oct 29, 2026

Study contacts

Dianna Auman, RN
Contact
Dianna.Roesler@Advocatehealth.org
336-716-1122
Madelyn Burkart, MD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nexatoclax

Start the discussion